Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

NCT05312216 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Durvalumab plus Lenvatinib

Sponsor

Zhejiang University